Ensign Peak Advisors, Inc Novo Cure LTD Transaction History

Ensign Peak Advisors, Inc

$51.2 Billion
Q1 2025

A detailed history of Ensign Peak Advisors, Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 39,137 shares of NVCR stock, worth $573,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,137

Previous 39,137 -0.0%

Holding current value

$573,748

Previous $1.17 Million 40.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.83 - $24.05 $28,392 - $57,720	2,400 Added 6.53%	39,137 $670,000
Q1 2024 May 14, 2024	SELL	$12.42 - $17.29 $74,867 - $104,224	-6,028 Reduced 14.1%	36,737 $574,000
Q4 2023 Feb 14, 2024	SELL	$11.13 - $15.78 $151,701 - $215,081	-13,630 Reduced 24.17%	42,765 $638,000
Q3 2023 Nov 13, 2023	BUY	$16.15 - $42.35 $349,243 - $915,818	21,625 Added 62.19%	56,395 $910,000
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $212,731 - $435,652	5,280 Added 17.9%	34,770 $1.44 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $36,686 - $77,226	650 Added 2.25%	29,490 $1.77 Million
Q4 2022 Feb 13, 2023	BUY	$63.98 - $85.37 $268,716 - $358,554	4,200 Added 17.05%	28,840 $2.12 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $422,854 - $594,175	-7,030 Reduced 22.2%	24,640 $2.04 Million
Q4 2021 Feb 11, 2022	BUY	$75.08 - $121.99 $1.82 Million - $2.96 Million	24,305 Added 330.01%	31,670 $2.38 Million
Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $157,410 - $263,615	1,355 Added 22.55%	7,365 $856,000
Q2 2021 Aug 13, 2021	BUY	$130.4 - $225.58 $783,704 - $1.36 Million	6,010 New	6,010 $1.33 Million

Others Institutions Holding NVCR

# of Institutions

285

Shares Held

77.5M

Call Options Held

943K

Put Options Held

155K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.54B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Novo Cure LTD Transaction History